ENTVAX002 - COVID-19 Booster Vaccine

COVID-19 unfortunately remains a public health issue, causing significant morbidity and mortality in at-risk patients. Despite the availability of vaccines, gaps remain, such as limited vaccine durability that requires frequent boosters and cold chain supply requirements limiting access to certain areas of the world.

ENTVAX002 is a COVID-19 booster vaccine that delivers a pDNA cargo in an optimized Fusogenix PLV vaccine formulation currently being evaluated in a phase I/II clinical trial. ENTVAX002 has the following potential advantages over the currently available COVID-19 vaccines:

· Longer durability leading to less frequent boosters

· Elicits strong T-cell response

· Economical manufacturing with pDNA

· Fridge-stable vaccine removes the cold-chain requirements of the currently available vaccines which improves access to effective vaccines for everybody.

Learn more about our ongoing clinical trial here.